Lineage Cell Therapeutics, Inc. (LCTX) Operating Margin % [USD] 2020 - 2024

Historical data

Taxonomy & unit
ratio: %
Description
The operating margin measures the profit a company makes on a dollar of sales after accounting for the direct costs involved in earning those revenues.
Summary
Lineage Cell Therapeutics, Inc. quarterly/annual Operating Margin history and growth rate from 2020 to 2024.
  • Lineage Cell Therapeutics, Inc. Operating Margin for the quarter ending March 31, 2024 was -309 %, a 61% decline year-over-year.
  • Lineage Cell Therapeutics, Inc. annual Operating Margin for 2023 was -277 %, a 80.5% decline from 2022.
  • Lineage Cell Therapeutics, Inc. annual Operating Margin for 2022 was -153 %, a 86.5% increase from 2021.
  • Lineage Cell Therapeutics, Inc. annual Operating Margin for 2021 was -1.13 K %, a 21.7% increase from 2020.
Operating Margin, Quarterly (% [USD])
Operating Margin, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Start Date End Date
Q1 2024 -309 -117 -61% Jan 1, 2024 Mar 31, 2024
Q4 2023 -277 -123 -80.5% Oct 1, 2023 Dec 31, 2023
Q3 2023 -285 +31 +9.81% Jul 1, 2023 Sep 30, 2023
Q2 2023 -224 +122 +35.2% Apr 1, 2023 Jun 30, 2023
Q1 2023 -192 +336 +63.7% Jan 1, 2023 Mar 31, 2023
Q4 2022 -153 +980 +86.5% Oct 1, 2022 Dec 31, 2022
Q3 2022 -316 +445 +58.5% Jul 1, 2022 Sep 30, 2022
Q2 2022 -346 +1.12 K +76.4% Apr 1, 2022 Jun 30, 2022
Q1 2022 -529 +1 K +65.5% Jan 1, 2022 Mar 31, 2022
Q4 2021 -1.13 K +315 +21.7% Oct 1, 2021 Dec 31, 2021
Q3 2021 -761 Jul 1, 2021 Sep 30, 2021
Q2 2021 -1.46 K Apr 1, 2021 Jun 30, 2021
Q1 2021 -1.53 K Jan 1, 2021 Mar 31, 2021
Q4 2020 -1.45 K Oct 1, 2020 Dec 31, 2020
* An asterisk sign (*) next to the value indicates that the value is likely invalid.